Medix Infusion

Medix Infusion provides specialized infusion therapy solutions for chronically ill and high-acuity patients, offering both clinic-based and home infusion services tailored to patient needs. Medix Infusion is a company focused on delivering infusion therapy services, emphasizing both clinic and home settings. Founded by Gus D. , the company has its headquarters in the United States.

Medix Infusion completed its most recent funding round, a Series B, on January 9, 2023, raising USD 35. 000 mn, led by Echo Health Ventures with participation from Noro-Moseley Partners and Pittco Management. The total amount raised by the company stands at USD 35. 000 mn with a current valuation of USD 96.

707 mn. Medix Infusion specializes in providing infusion therapy solutions for chronically ill and high-acuity patients. Their primary offerings include clinic-based and home infusion services, ensuring that patients have access to critical therapies in convenient settings. The company operates a state-of-the-art home infusion pharmacy, featuring advanced clean-room facilities that guarantee safe medication preparation and efficient delivery.

Additionally, Medix Infusion emphasizes a comprehensive intake model covering insurance authorization, benefit verification, scheduling, and patient communication, primarily serving patients, healthcare providers, and referring physicians in underserved markets across rural and suburban regions in the United States. Medix Infusion generates revenue through a structured service model, encompassing both clinic visits and home infusion therapies. The company operates on a direct-to-consumer basis, allowing patients to schedule appointments for their infusion treatments at multiple clinic locations. Revenue is derived from charges for individual infusion therapy sessions, with pricing dependent on the specific treatments and services rendered.

The company collaborates with healthcare providers and insurance companies to facilitate patient access, involving agreements on reimbursement rates and service fees, allowing Medix Infusion to cater to a diverse patient base while focusing on quality care and operational efficiency. In January 2023, Medix Infusion raised USD 35. 000 mn in Series B funding, led by Echo Health Ventures, to support its organic growth and to acquire the infusion operations of the Center for Neurology and Spine. This funding will enhance the company’s capabilities and service reach, enabling an anticipated expansion into additional geographic markets.